Biochaperone® prandial combinations for t1d

ENABLING 2-in-1 MULTI-HORMONAL TREATMENTS TO IMPROVE LONG-TERM OUTCOMES IN TYPE 1 DIABETES

While insulin is a life-saving treatment for people with type 1 diabetes, even optimally controlled patients exhibit profound glycemic variability and frequently fail to reach their treatment goals. This may result in a higher risk of severe complications in the long term, such as cardiovascular disease, retinopathy, kidney failure or neuropathy.

In people without diabetes, insulin is actually secreted in synchrony, and acts in synergy, with other hormones, such as amylin and GLP-1, to control blood glucose.

In type 1 diabetes, ultimately, neither insulin nor amylin is secreted and GLP-1 secretion is deficient (cf. below). Hence, the use of insulin alone may not be enough to address the whole spectrum of diabetes-related metabolic deficiencies.

Hormonal pattern

1 Source: Adocia, adapted from Toff-Neilsen et al, J. Clin Endocrinol Metab 2001;86:3717-3723; Cummings DE et al, Diabetes 2001;50:1714-1719; Aronoff SL et al, Diabetes Spectrum 2004; 17(3): 183-190

 

Both pramlintide (Symlin®, AstraZeneca), a short-acting amylin analog, and exenatide (Byetta®, AstraZeneca), a short-acting GLP-1 receptor agonist, have been approved for the treatment of type 1 and type 2 diabetes, respectively. It has been demonstrated in clinical trials that, when added to an existing insulin regimen, these molecules improve HbA1c and reduce prandial insulin consumption, weight gain and side effects 1,2.

However, insulin therapy for people with type 1 diabetes already requires intense patient involvement, including multiple daily injections (up to four or more) and frequent glucose monitoring. Hence, adding a new injectable treatment (up to thrice daily in the cases of pramlintide or exenatide) may be a real challenge. To maintain patient persistency, new treatment options should avoid adding to the burden of treatment management and remain affordable.

BC PRANDIAL COMBINATIONS FOR T1D: BC LISPRO PRAMLINTIDE & BC LISPRO EXENATIDE

etudiantAdocia is working to provide significant medical benefit to people living with type 1 diabetes by restoring the synergistic effect of insulin with other metabolic hormones.

Using BioChaperone® to combine complementary agents with insulin lispro, Adocia thus develops two easy-to-use, 2-in-1 combinations products:

  • BioChaperone Lispro Pramlintide
  • BioChaperone Lispro Exenatide

Our BioChaperone formulation strategy, based on real-world clinical data demonstrating clear medical benefit with the separate hormones, could shorten development time. The BioChaperone projects also have the potential to support competitive pricing by leveraging approved, off-patent or soon to be off-patent proteins.

The BioChaperone Prandial Combinations program, first announced on January 5th 2017, is currently in preclinical development. Based on established expertise in developing innovative formulations with our BioChaperone technology, Adocia aims to test one of these candidates in a clinical study in Q4 2017.

1. Karl D, et al. Diabetes Technol Ther 2007; 9(2):191-199.
2. Raman VS, et al. Diabetes Care 2010 Jun; 33(6): 1294-1296.

TOP